Radiopharm Theranostics Limited American Depositary Shares (RADX) — Net Asset Momentum
Radiopharm Theranostics Limited American Depositary Shares (RADX) recorded a net asset momentum of 56.7% as of June 2025, with net assets of $42.87 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Explore Radiopharm Theranostics Limited American (RADX) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
YoY Momentum
Current Net Assets
Years of Data
Country
Radiopharm Theranostics Limited American Depositary Shares Net Asset Momentum (2022–2025)
This chart tracks Radiopharm Theranostics Limited American Depositary Shares's year-over-year net asset growth across 4 annual reporting periods from 2022 to 2025. The most recent momentum reading is +56.7%, with net assets of $42.87 Million USD as of June 2025. See Radiopharm Theranostics Limited American (RADX) flexibility index to measure the company's free cash flow as a share of total liabilities.
Annual Net Asset History for Radiopharm Theranostics Limited American Depositary Shares (2022–2025)
The table below shows the complete annual net asset history for Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2025, covering 4 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see RADX market cap overview.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | $42.87 Million | $86.48 Million | $43.61 Million | ▲ +56.7% |
| 2024 | $27.35 Million | $72.04 Million | $44.68 Million | ▼ -40.0% |
| 2023 | $45.58 Million | $74.95 Million | $29.37 Million | ▼ -27.6% |
| 2022 | $62.96 Million | $83.38 Million | $20.42 Million | — |